However, further research is warranted to evaluate whether circulating FGF21 can be used as a biomarker alone or as part of a multi-biomarker panel that includes BNP and other biomarkers to improve the accuracy of diagnosis and prognosis in individuals with HF. The gene discussed is FGF21; the disease is hydrops fetalis.